Skip to main content
Top
Published in: Trials 1/2024

Open Access 01-12-2024 | Nitrous Oxide | Study protocol

A nitrous oxide/oxygen fixed mixture to reduce pain induced by the hypodermic injection: study protocol for a randomized, controlled trial

Authors: Jun-Jun Zhang, Ping Yu, Hui Dang, Cheng-Shuang Feng, Xiu-Jiang Long, Wen-Fa Huang, Lei Wang, Jie-Ling Li, Guo-Liang Tian, Jia-Quan Wen, Jun-Hui Mei, Yu-Xiang Li

Published in: Trials | Issue 1/2024

Login to get access

Abstract

Background

Patients with hematological malignancies received multiple hypodermic injections of recombinant human granulocyte colony-stimulating factor. Procedural pain is one of the most common iatrogenic causes of pain in patients with hematological malignancies. It is also identified as the most commonly occurring problem in clinical care in the Department of Hematology and Oncology at Shenzhen University General Hospital. However, providing immediate relief from pain induced by hypodermic injection of recombinant human granulocyte colony-stimulating factor remains a major challenge. This trial aims to evaluate the safety and analgesic efficacy of a fixed nitrous oxide/oxygen mixture for patients with hematological malignancies and experiencing procedural pain caused by hypodermic injection of recombinant human granulocyte colony-stimulating factor in the department.

Methods

The nitrous oxide/oxygen study is a single-center, randomized, double-blind, placebo-controlled trial involving patients with hematological malignancies who require hypodermic injections of recombinant human granulocyte colony-stimulating factor for treatment. This trial was conducted in the Hematology and Oncology Department of Shenzhen University General Hospital. A total of 54 eligible patients were randomly allocated to either the fixed nitrous oxide/oxygen mixture group (n = 36) or the oxygen group (n = 18). Neither the investigators nor the patients known about the randomization list and the nature of the gas mixture in each cylinder. Outcomes were monitored at the baseline (T0), immediately after hypodermic injection of recombinant human granulocyte colony-stimulating factor (T1), and 5 min after hypodermic injection of recombinant human granulocyte colony-stimulating factor (T2) for each group. The primary outcome measure was the score in the numerical rating scale corresponding to the highest level of pain experienced during hypodermic injection of recombinant human granulocyte colony-stimulating factor. Secondary outcomes included the fear of pain, anxiety score, four physiological parameters, adverse effects, total time of gas administration, satisfaction from both patients and nurses, and the acceptance of the patients.

Discussion

This study focused on the safety and analgesic efficacy during hypodermic injection of recombinant human granulocyte colony-stimulating factor procedure. Data on the feasibility and safety of nitrous oxide/oxygen therapy was provided if proven beneficial to patients with hematological malignancies during hypodermic injection of recombinant human granulocyte colony-stimulating factor and widely administered to patients with procedural pain in the department.

Trial registration

Chinese Clinical Trial Register, ChiCTR2200061507. Registered on June 27, 2022. http://​www.​chictr.​org.​cn/​edit.​aspx?​pid=​170573&​htm=​4
Appendix
Available only for authorised users
Literature
9.
go back to reference Mao J. Histology and embryology. 9th ed. Beijing: People’s Sanitary Publishing Press; 2015. Mao J. Histology and embryology. 9th ed. Beijing: People’s Sanitary Publishing Press; 2015.
15.
Metadata
Title
A nitrous oxide/oxygen fixed mixture to reduce pain induced by the hypodermic injection: study protocol for a randomized, controlled trial
Authors
Jun-Jun Zhang
Ping Yu
Hui Dang
Cheng-Shuang Feng
Xiu-Jiang Long
Wen-Fa Huang
Lei Wang
Jie-Ling Li
Guo-Liang Tian
Jia-Quan Wen
Jun-Hui Mei
Yu-Xiang Li
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Trials / Issue 1/2024
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-024-07919-y

Other articles of this Issue 1/2024

Trials 1/2024 Go to the issue